Neurocrine Biosciences (NBIX) Return on Capital Employed Growth (5y) (2016 - 2026)
Neurocrine Biosciences (NBIX) Return on Capital Employed Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.46 Bn | 87.60 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.93 Bn | 32.19 Bn | 1.97 Bn |
| 3 | Zoetis | 32.54 Bn | 30.60 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.49 Bn | 23.43 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.05 Bn | 20.89 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.24 Bn | 18.43 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.45 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.60 Bn | 12.17 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,157.00 |
| Dec 31, 2025 | 533.00 |
| Sep 30, 2025 | 41.00 |
| Jun 30, 2025 | -1,643.00 |
| Mar 31, 2025 | -389.00 |
| Dec 31, 2024 | 762.00 |
| Sep 30, 2024 | 1,486.00 |
| Jun 30, 2024 | 1,689.00 |
| Mar 31, 2024 | 2,049.00 |
| Dec 31, 2023 | 627.00 |
| Sep 30, 2023 | 378.00 |
| Jun 30, 2023 | 1,230.00 |
| Mar 31, 2023 | 1,823.00 |
| Dec 31, 2022 | 3,223.00 |
| Sep 30, 2022 | 3,300.00 |
| Jun 30, 2022 | 4,860.00 |
| Mar 31, 2022 | 7,198.00 |
| Dec 31, 2021 | 4,760.00 |
| Sep 30, 2021 | 4,596.00 |
| Jun 30, 2021 | 3,816.00 |